| DB ID | MyCo_3048 |
| Title | (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis |
| Year | 2012 |
| PMID | 22573851 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | parapsilosis |
| Organism | Candida parapsilosis |
| Ethical Statement | The institutional review committee of each participating site approved the study with its ClinicalTrials.gov identifier NCT00496197. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Two hundred fifty-seven patients with proven candidemia/IC, selected from patients that were enrolled in a Pfizer clinical trial evaluating anidulafungin therapy for candidemia and IC in the United States, consented to participate in the study. The inclusion criteria included male and female patients (≥18 years) with or without neutropenia (absolute neutrophil count <500 cells/µL) who had the diagnosis of candidemia (at least 1 blood culture positive for yeast) or proven IC with tissue infections ( positive culture for yeast from a normally sterile site), according to EORTC/MSG criteria. |
| Cohort No. | 257 |
| Age Group | 19–91 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
